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Abstract
Background
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited treatment
options in which the telomere shortening is a strong predictive factor of poor prognosis. Mes-
enchymal stromal cells (MSC) administration is probed in several experimental induced
lung pathologies; however, MSC might stimulate fibrotic processes. A therapy that avoids
MSC side effects of transformation would be an alternative to the use of living cells. Mem-
branes particles (MP) are nanovesicles artificially generated from the membranes of MSC
containing active enzymes involved in ECM regeneration. We aimed to investigate the anti-
fibrotic role of MP derived from MSC in an in vitro model of pulmonary fibrosis.
Methods
Epithelial cells (A549) and lung fibroblasts, from IPF patients with different telomere length,
were co-cultured with MP and TGF-β for 48h and gene expression of major pro-fibrotic
markers were analyzed.
Results
About 90% of both types of cells effectively took up MP without cytotoxic effects. MP
decreased the expression of profibrotic proteins such as Col1A1, Fibronectin and PAI-1, in
A549 cells. In fibroblasts culture, there was a different response in the inhibitory effect of MP
on some pro-fibrotic markers when comparing fibroblast from normal telomere length
patients (FN) versus short telomere length (FS), but both types showed an inhibition of
Col1A1, Tenascin-c, PAI-1 and MMP-1 gene expression after MP treatment.
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Conclusions
MP conserve some of the properties attributed to the living MSC. This study shows that MP
target lung cells, via which they may have a broad anti-fibrotic effect.
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common form of the idiopathic interstitial
pneumonias. It is a chronic, progressive, irreversible, and lethal lung disease of unknown
cause. IPF occurs in middle-aged and elderly adults [1–3] with a median survival of 2–4 years
[2] after diagnosis. Telomere shortening is a strong predictive factor of poor prognosis [1, 4–
6]; patients with IPF and short telomeres have more rapid disease progression [5]. The patho-
genic mechanisms remain unclear, but a growing body of evidence indicates that the disease is
the result of an abnormal behavior of the alveolar epithelial cells that provoke the migration,
proliferation, and activation of mesenchymal cells, with the formation of fibroblast and myofi-
broblast foci [1]. It has been described that transforming growth factor (TGF)-β plays a crucial
role as a pro-fibrotic cytokine [7]. Activated myofibroblasts secrete exaggerated amounts of
extracellular matrix (ECM) molecules with the subsequent destruction of the lung architecture
[1, 8], resulting in respiratory failure [9]. Although numerous therapies have been evaluated in
patients with IPF [10], pirfenidone [11] and nintedanib [12] are the only treatments that slow
down disease progression [13] but are not fully effective at reducing mortality. Thus, there is
an urgent need to identify novel therapeutic targets for IPF [10] that will reverse or stop the
progression of the disease [1, 3].
Accordingly, the use of stem cells to improve regeneration and reduce fibrosis has been
reported in animal models of lung fibrosis [14–17]. Very recently, three phase 1 clinical trials
demonstrated the feasibility and safety of administration of mesenchymal stromal cells (MSC)
in IPF patients [18–20]. It is well established that MSC exert their therapeutic effect via secre-
tion of bioactive products such as cytokines, growth factors, and extracellular vesicles (EV)
[21]. EV derived from MSC have been found to promote therapeutic activities that are compa-
rable to MSC themselves such as the suppression of pro-inflammatory processes and reduction
of oxidative stress, pulmonary fibrosis and tissue remodeling in a variety of in vivo inflamma-
tory lung disease models by transferring their components [22]. The major advantage of MSC-
derived EV therapy over live-cell transplantation can be attributed to the inherent risks and
limitations associated with live-cell transplants. However, the production of EV results a major
challenge as, the available protocols to isolate EV do not avoid the co-precipitation of contami-
nant proteins non-associated to EV, such as soluble growth factor produced by the cells as it is
described by the International Society of Extracellular Vesicles [23]. Furthermore, there is het-
erogeneity in EV molecular content due to the active process of EV release that depends on the
different stimuli received by the origin cell [24]. Finally, the low yield of EV originated by the
cells makes difficult a scalable production of these vesicles as therapeutic product [21, 22].
Recently, we have generated nanovesicles from the membranes of MSC named membrane
particles (MP) [25]. This novel product shows a size smaller than 200 nm, and spherical shape,
properties shared with EV. The main advantage of MP respect to another type of vesicles is the
high yield of MP obtained per cell. The scalable production of MP makes them an attractive
pharmaceutical product. We also showed that MP have comparable functional effects to MSC,
such as immunomodulation [25], and endothelial regeneration [26]. These previous studies
suggested that MP could have other therapeutic effects described for MSC such as their antifi-
brotic capacity.
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In the current study, we used an in vitro fibrosis model based on the stimulation with TGF-
β of bronchial alveolar human epithelial cells (A549) and fibroblasts from IPF patients with
different length of telomere to investigate the anti-fibrotic role of MP derived from human adi-
pose tissue mesenchymal stem cell (AT-MSC)
Materials and methods
Ethics statement and human tissue samples
Human AT-MSC were isolated from subcutaneous adipose tissue from healthy kidney donors
available during kidney donation procedures. The tissues were collected after obtaining writ-
ten informed consent, as approved by the Medical Ethical Committee of the Erasmus Univer-
sity Medical Centre Rotterdam (protocol no. MEC-2006-190).
Isolation and culture of AT-MSC
AT-MSC were isolated from subcutaneous adipose tissue of four healthy donors (1 female/
3males). The range of age of the donors was between 34–78 years old. The adipose tissue was
mechanically disrupted and enzymatically digested with 0.5 mg/ml collagenase type IV
(Sigma-Aldrich, St. Louis, MO) in RPMI medium for 30 min at 37˚C under continuous shak-
ing. Thereafter, the cells were resuspended in MEM-αmedium containing 10% inactivated
fetal bovine serum (FBS) (Lonza, Verviers, Belgium), 2 mM L-glutamine and 1% penicillin/
streptomycin, filtered through a 100 μm cell strainer, and transferred to 175 cm2 culture flasks
(Greiner Bio-one, Essen, Germany). At 90% confluence AT-MSC (passage 2–6) were collected
to generate cell MP.
Generation and characterization of membrane particles from AT-MSC
As we described previously [25], AT-MSC were osmotically lysed by incubating them in ultra-
pure H2O at 4˚C until the cells liberated their nuclei. Cell extracts were cleared of unbroken
cells and nuclei by centrifugation at 2,000 x g for 20 min. After discarding the nuclei, samples
were transferred to Amicon Ultra-15 filter tubes (100 kDa pore size) and concentrated the
crude membranes by centrifugation at 4,000 x g at 4˚C. The concentrated cell membranes
were diluted in 0.2 μm filtered PBS.
A population of MP, with a size below 200 nm was obtained by extruding the cell mem-
branes gradually through different pore size filters, first 800 nm, second 400 nm and third 200
nm to avoid the blockade of the smaller final pore size filter [27] (Merck, KGaA, Darmstadt,
Germany).
The extrusion process was performed using LiposoFast LF-50 device (AVESTIN Europe,
Mannheim, Germany) at a pressure of 20 psi to force the MP to pass through the filters. All
procedures were performed on ice.
The preparations of MP were visualized by cryo-transmission electron microscopy (Cryo-
TEM). A thin aqueous film was formed by applying a 3 μl droplet of MP suspension to a speci-
men bare EM grid. Glow-discharged holey carbon grids were used. After the application of the
suspension, the grid was blotted against filter paper, leaving a thin sample film spanning the
grid holes. These films were vitrified by plunging the grid into ethane, which was kept at its
melting point by liquid nitrogen, using a Vitrobot (Thermo Fisher Scientific Company, Eind-
hoven, Netherlands) and keeping the sample before freezing at 95% humidity. The vitreous
sample films were transferred to a Tecnai Arctica microscope (Thermo Fisher Scientific, Eind-
hoven, Netherlands). Images were taken at 200 Kv with a field emission gun using a Falcon III
(Thermo Fisher Scientific) direct electron detector. The analysis of absolute size distribution
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and concentration of MP was performed by Nanoparticle tracking analysis (NTA) using
NanoSight NS300 (NanoSight Ltd.). The NTA measurement conditions were: detect threshold
3, three measurements per sample (30 s/measurement), temperature 23.61 ± 0.8˚C; viscosity
0.92 ± 0.02 cP, 25 frames per second. Each video was analyzed to obtain the mean, mode,
median and estimated concentration for each particle size.
Sample preparation and proteomic data analysis
MP were lysed in an ice-cold buffer containing 100 mM Tris-HCl (pH 8.5), 12 mM sodium
DOC and 12 mM sodium N-lauroylsarcosinate. The lysate was sonicated for 10 min and boiled
for 5 min at 95˚C. Proteins were subjected to reduction with dithiothreitol, alkylation with
iodoacetamide and then in-solution digested with trypsin (sequencing grade. Promega). Pro-
teolytic peptides were collected, washed and analyzed by liquid chromatography tandem mass
spectrometry (nLC-MS/MS) performed on an EASY-nLC coupled to an Orbitrap Fusion
Lumos Tribid mass spectrometer (Thermo) operating in positive mode. Peptides were sepa-
rated on a ReproSil-C18 reversed-phase column (Dr Maisch; 15 cm × 50 μm) using a linear
gradient of 0–80% acetonitrile (in 0.1% formic acid). Spectra were acquired in continuum
mode; fragmentation of the peptides was performed in data-dependent mode by HCD.
Raw mass spectrometry data were analyzed with the MaxQuant software suite [28] with the
additional options ‘LFQ’ and ‘iBAQ’ selected. The Andromeda search engine was used to
search the MS/MS spectra against the Uniprot database taxonomy: Homo sapiens, (release:
June 2019) concatenated with the reversed versions of all sequences. A maximum of two
missed cleavages was allowed. The peptide tolerance was set to 10 ppm and the fragment ion
tolerance was set to 0.6 Da for HCD spectra. The enzyme specificity was set to trypsin and cys-
teine carbamidomethylation was set as a fixed modification. Both the PSM and protein FDR
were set to 0.01. In case the identified peptides of two proteins were the same or the identified
peptides of one protein included all peptides of another protein, these proteins were combined
by MaxQuant software suite and reported as one protein group. Before further statistical anal-
ysis, known contaminants and reverse hits were removed.
Proteomic data analysis Panther Pathway was used to detect the protein pathways involved
in fibrosis in each sample and the number of proteins of each pathway represented in each
sample (www.pantherdb.com).
Matrix metalloproteinases (MMPs) activity
MMPs activity of MP was analyzed by fluorimetric assay (MMP Activity Assay Kit, ab112146;
Abcam) following the recommended protocol. Two amounts of MP (5x109 MP and 2.5x109
MP) were incubated with 2 mM 4-Aminophenylmercuric Acetate (APMA) during 3 h to acti-
vate the MMP. MP without APMA activation, and MP incubated with 10 μM of GM6001 (a
pan-matrix metalloproteinase inhibitor) (ab120845; Abcam) after 3h with APMA were used as
controls of the technique. The assay is based on a fluorescence resonance energy transfer
(FRET) peptide as a generic MMP activity indicator. In the intact FRET peptide, the fluores-
cence of one part is quenched by another. After cleavage into two separate fragments by
MMPs, the fluorescence is recovered. The signal was detected by a fluorescence microplate
reader at Ex/Em = 490/525 nm.
Lung epithelial cell line culture
Bronchial-alveolar epithelial human cells (A549) were purchased from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and cultured in F12K (Gibco Life Technolo-
gies, Grand Island, NY, USA) medium supplemented with 10% inactivated FBS (Gibco Life
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Technologies) and penicillin (100 U/ml) / streptomycin (100 μg/ml) solution (Gibco Life
Technologies) according to the manufacturer´s recommendations. Cells were maintained at
37˚C in a humidified 5% CO2 atmosphere.
Isolation of primary human lung fibroblasts
Adult human lung fibroblasts were obtained from lung biopsies of IPF patients who under-
went surgical biopsy for the diagnosis of the disease (histologically confirmed usual interstitial
pneumonia) [2]. The tissues were collected after obtaining written informed consent, as
approved by and Ethics Committee of Bellvitge Hospital (CEIC, ref. PR202/08). The harvested
lung tissue samples were maintained in a solution containing DMEM high Glucose with L
Glutamine (Gibco Life Technologies) medium, HEPES (Sigma-Aldrich, St Louis, MO, USA)
and insulin human transferrin and sodium selenite (ITS) (Sigma-Aldrich) until processing.
Then, samples were cut into small pieces, and placed into six well plates (Nunc Thermo Scien-
tific, Waltham, MA, USA) with growth medium; DMEM supplemented with 10% inactivated
FBS (Gibco Life Technologies), penicillin (100 U/ml)/streptomycin (100 μg/ml) solution
(Gibco Life Technologies) and 25 μg/ml amphotericin B (Sigma-Aldrich). Cells were cultured
at 37˚C in a humidified atmosphere of 5% CO2. Spindle-like primary fibroblasts started to
grow out from tissue samples on day 2 to 3. Outgrowth of fibroblasts took 1 to 2 weeks. Tissue
samples were then removed by aspiration, and cells were allowed to reach confluence. Fibro-
blasts at confluence were expanded by trypsinization and passaged every 4 to 5 days at 1:4
ratio. Cells between passages 4 and 7 were used in this study.
Telomere length of IPF patients
IPF patients were divided into two groups according to the telomere length (TL). TL analysis
was performed using DNA samples isolated from mouth epithelial cells and peripheral blood
mononuclear cells (PBMC). Oral swabs (Isohelix, SK-2S, Cell Projects Ltd), previously vali-
dated in normal and with other telomeropathies subjects, were used for collection of cheek epi-
thelial cells and DNA was extracted using a commercial kit (Isohelix, Cell Projects Ltd) [29–
31]. DNA was obtained from PBMC, and the relative TL was assessed by quantitative polymer-
ase chain reaction (qPCR) as previously described [32], and then was confirmed by Southern
blot. The qPCR determines the ratio of telomere (T) repeat copy number to single-copy (S)
gene (36B4) copy number (T/S ratio) in experimental samples, as compared with a reference
DNA sample. This methodology was also validated for the TL measurement in buccal cells. As
TL changes with age, a z-score value was obtained to allow the comparisons between individu-
als of different ages. The z-score compared the T/S value in each individual with the age-
matched mean and SD of the values obtained in the controls (individual’s value–population
mean/population SD, age-matched population of within 9 years on average). The z-score
below the 25th percentile of a normal distribution was considered telomere shortening. Severe
TL reduction was identified when z-score was below the 1st percentile. Telomere shortening
was also measured from blood DNA of each patient by Southern blot analysis of telomere
restriction fragment (TRF) (TeloTAGGG Telomere Length Assay, Roche), which was consid-
ered the gold standard [32, 33].
Human lung cell cultures treated with AT-MSC under TGF-β conditions
Human lung primary fibroblasts and A549 cell line were cultured in six well plates (Nunc
Thermo Scientific) in the appropriated medium with 10% inactivated FBS; when cells reached
80% confluence the medium was changed to 2% inactivated FBS. Cells were stimulated with
activated TGF-β (5 ng/ml) (R&D Systems Minneapolis, MN, USA) in the presence of several
PLOS ONE Anti-fibrotic effect of AT-MSC membrane particles
PLOS ONE | https://doi.org/10.1371/journal.pone.0248415 March 17, 2021 5 / 20
doses of MP from AT-MSC (10,000; 50,000; and 100,000 MP/cell) during 48 h. After the incu-
bation period, cells and supernatants were collected, then separated by centrifugation, and fro-
zen at -80˚C for further analysis.
Toxicity assay
Cell viability was evaluated using a commercial colorimetric assay (Quick Cell Proliferation
Assay Kit II. MBL, International Corporation, Woburn, MA, USA) according to the recom-
mended protocol. Cells (5 × 104/well) were cultured in a 96-well microtiter plate (Nunc
Thermo Scientific) and treated with different cell:MP ratio (1:10,000; 1:50,000 and 1:100,000)
in a final volume of 100 μl/well of 2% FBS culture medium in triplicates for 48 h. Then, 10 μl/
well of WST reagent was added and plates were incubated for 4 h at 37˚C in standard culture
conditions. After shaking the plates for 1 min, the absorbance was computed at a wavelength
of 420 nm in each well using a microplate reader (Thermo Scientific) with 650 nm of reference
wavelength. The amount of the dye generated by activity of dehydrogenase is directly propor-
tional to the number of living cells.
Uptake of MP by A549 cells and fibroblasts
AT-MSC were labeled with red fluorescent PKH-26 dye according to the manufacturer’s pro-
tocol (Sigma-Aldrich) prior to generation of MP, enabling the generation of fluorescent MP
(PKH-MP). A549 and lung fibroblasts were plated at a density of 2 x 105 cells/well on a 12 well
plate. Three ratios of PKH-MP, (1:10,000; 1:50,000 and 1:100,000) were added to the cultures
for 24 h and 48 h. Then, the same protocol was performed by adding TGF-β (5 ng/mL) and the
three ratios of PKH-MP for 48h. The uptake of MP by the cells was quantified by flow cytome-
try. The data were analyzed using Kaluza Software (Beckman Coulter).
For confocal microscopy images, Carboxyfluorescein succinimidyl ester (CFSE) was used
to stain the A549 cells. The surface membrane of the fibroblasts was labeled with anti-CD44
and anti-CD90 antibodies both conjugated in APC. The nuclei of both types of cells were
stained with 10μM Hoechst 33342 (Sigma). PKH-MP uptake by cells was imaged by a Leica
TCS SP5 confocal microscope (Leica Microsystems B.V., Science Park Eindhoven, Nether-
lands), equipped with Leica Application Suite Advanced Fluorescence (LAS AF) software,
DPSS 561 nm lasers, using a 60 X (1.4 NA oil) objective. Microscope images were processed
using ImageJ 1.48 (National Institutes of Health, Washington, USA).
RNA extraction and real-time polymerase chain reaction (RT-qPCR)
Total RNA was isolated from cultured cells using the Qiagen RNeasy Mini Kit (Qiagen, Valen-
cia, CA, USA) according to the manufacturer’s recommendations. Samples were digested with
DNase I (Qiagen) to remove contaminating genomic DNA. One μg of RNA was reverse-tran-
scribed using the iScript cDNA synthesis kit (Bio Rad) with oligo deoxythymidine and random
hexamer primers. The reverse transcriptase reaction proceeded in a total volume of 20 μl in a
conventional thermal cycler (Bio-Rad) at 25˚C for 5 min, followed by 30 min at 42˚C and 5
min at 85˚C. Reaction volumes of 20 μl were placed in 384-well optical reaction plates with
adhesive covers (ABI Prism™ Applied Biosystems, Foster City, CA, USA) using SYBR Green
PCR Master Mix and specific sequence primers (Sigma). The relative gene expression (RGE)
of each targeted gene was normalized by subtracting the corresponding housekeeping genes
(β-actin, HPRT and RNA18s) threshold cycle (Ct) value using the comparative Ct method
(ΔΔCt methods).
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Western blot assay
Cells were lysed in Radio-Immunoprecipitation Assay (RIPA) Buffer (25 mM Tris-HCl, 150 mM
NaCl, 1% NP-40, 0.1% sodium deoxycholate SDS) containing 1:100 phenylmethylsulfonyl fluo-
ride and phosphatase inhibitors (Sigma). Prepared samples were heated at 100˚C for 4 min; for
each sample the same amount of total protein (10 μg) was added to a well of 4–15% mini-protean
TGX precast gels polyacrylamide gel (Bio-Rad Hercules, CA, USA) and resolved by SDS-PAGE.
The separated proteins were transferred to a nitrocellulose membrane (Bio-Rad). The membranes
were blocked for 1 h in Tris-buffered saline (10 mM Tris-HCl pH7.5 and 0.15 M NaCl) contain-
ing 0.1% (v/v) Tween 20 and 5% (w/v) bovine serum albumin (BSA) (Sigma-Aldrich), and then
probed at room temperature (RT) for 1 h with primary antibodies against human EDA-fibronec-
tin (diluted 1:400, Abcam). Immunoreactive bands were detected with IgG horseradish peroxi-
dase-conjugated secondary antibodies (anti-mouse diluted 1:1,000) (Dako, Glostrup, Denmark)
and visualized by enhance chemiluminescence detection reagents ECL Western blotting kit (Bio-
Rad) according to the manufacturer´s instructions in a luminescent image analyzer (Chemi Doc
Bio-Rad) and were then scanned for densitometry analysis (Image Lab Bio-Rad).
ELISA
Levels of Tenascin-c and MMP-1 were measured in supernatants samples by Quantitative
sandwich enzyme immunoassay for human MMP-1 (R&D Systems) and Human Tenascin-c
large (FNIII-C) assay (IBL) according the manufacturer´s protocol.
Statistical analysis
All results were expressed as mean ± SEM of independent experiments. Statistical analysis was
performed using Graph Pad Prism 5.01 (Graph Pad Software, San Diego, CA, USA). Data
were analyzed by one-way ANOVA, with post hoc testing using Bonferroni multiple compari-




The included IPF patients were diagnosed following the 2011 European Respiratory Society
(ERS)/American Thoracic Society (ATS)/Japanese Respiratory Society/Latin American Tho-
racic Society Guidelines [2]. The final diagnosis was discussed and established by a multidisci-
plinary committee that includes expert ILD lung physicians, radiologists, and pathologists.
Video-thoracic lung biopsy was required in all of them. Table 1 describes the characteristics of
the patients at time of diagnosis and includes relevant clinical data such as gender, age,
Table 1. Patient’s demographics and characteristics.
TELOMERE LENGTH
PATIENT AGE AT DIAGNOSIS RELATIVE WITH IPF FVC% PREDICTED DLCO% PREDICTED T/S RATIO Z-SCORE PERCENTILE
#1 64 YES 77.6 60.6 0.728 -1.824 <1%
#2 70 YES 83.3 71.3 0.896 -2.251 <1%
#3 73 YES 74 42 0.890 -2.272 <1%
#4 66 NO 71.2 64.4 1.224 -0.515 50–25%
#5 77 NO 66.1 83.1 1.418 -0.126 50–25%
#6 73 YES 75.9 48 1.415 -0.140 50–25%
https://doi.org/10.1371/journal.pone.0248415.t001
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smoking history (packs per year), family history, and percentage of predicted value of lung
function (FVC and DLco) according to reference values described by the ATS/ERS guidelines:
standardisation of lung function testing [34, 35]. As telomere length is an important risk factor
for disease development and poor outcome, we divided the obtained lung fibroblasts for cell
culture experiments into two groups depending on the telomere length of the patients. Thus,
they were classified into fibroblasts from patients with normal telomere length compared to
age-matched controls, above the 25th percentile, designated as FN, and those with very short
telomere length, below the first age-adjusted percentile, designed as FS. The mean percent pre-
dicted forced vital capacity (FVC%) of short telomere group was 78.3 ± 4.3%, and mean per-
cent predicted carbon monoxide diffusing capacity (DLco%) was 57.9 ± 14.8%. For the normal
telomere length group, the mean of FVC% was 71 ± 4.9 and the mean of DLco% was
65.1 ± 17.5. No respiratory physiological significant differences were found between patients
with normal or shorten telomeres.
Characterization of MP generated from AT-MSC
Cryoelectron microscopy analysis showed that all MP have a round shaped appearance with a
discernible lipid bilayer (Fig 1A). The average size frequency of MP was 133.1± 22.1 nm (Fig
1B) and the average number of particles generated from each MSC was 1.3 x 105 ± 3.2 x 104
measured by NanoSight. The frequency of particles larger than 200 nm (cut-off pore size) was
lower than 0.5 ± 0.3% in the samples indicating homogeneity in size of the MP population.
From the 2,998 proteins detected by mass spectrometry, five clusters were involved in the
regulation of the ECM organization pathway. According to a classification based on the pro-
tein class, we observed protein modifying enzymes (metalloproteinase (MMP)-2 and 14) that
participate in the degradation of the ECM; and protein binding activity modulator (Bone mar-
row stromal antigen 2 (BST2), Reversion-inducing cysteine-rich protein with Kazal motifs
(RECK), and metalloproteinase inhibitor-3 (TIMP3)) that regulate the activity of both MMP-
2, and 14 (Fig 1C).
To evaluate whether these proteins maintain their functional activity, and were not
degraded during the generation of the MP, we performed a fluorimetric assay. MMP activity
was observed in a dose-dependent manner. The MMP activity of MP was totally suppressed by
adding the MMP inhibitor GM6001 during 15 min. Non-activated MMP were used as a back-
ground control for the assay (Fig 1D).
MP do not induce toxicity on A549 cells and human lung fibroblasts
The potential toxicity of MP on A549 and lung fibroblasts from FS and FN IPF patients were
determined by measuring the viability of these cells. Three cell:MP ratios (1:10,000; 1:50,000
and 1:100,000) were assayed for 48 h. Control cells were treated with the same volume of PBS.
None of the tested ratios showed a significant decrease in the viability of A549 (Fig 2A), FN
(Fig 2B) and FS (Fig 2C) compared to the PBS control.
MP are effectively taken up by A549 cells and human lung fibroblasts
Two experimental conditions were carried out to analyze the MP uptake by A549. First, cells
were cultured in presence of three ratios of fluorescent PKH-MP (cell:MP ratio 1:10,000;
1:50,000 and 1:100,000) during 24 and 48 h. The ratio of 10,000 MP per cell showed 45.1 ± 1.2
percentage of PKH26 positive A549 at 24 h and 52.9 ± 10.5 at 48 h. Probably, at the ratio of
10,000 MP per cell, the A549 cells did not accumulate enough PKH-MP inside to pass the fluo-
rescent threshold and to become a clear positive population in the flow cytometry. However, at
doses of 50,000 and 100,000 MP per cell, the percentage of PKH-MP positive cells reached the
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100% of positive signal for both 24 and 48 h time points (Fig 3A). These results indicated that
all cells were able to take up enough MP to be positive in the flow cytometry whether the doses
were 50,000 or 100,000 MP per cell.
Second, A549 cells under TGF-β stimulation showed similar efficacy in the MP uptake
compared to the non-stimulated condition (Fig 3B). Confocal microscope images were taken
and, as shown in Fig 3C, MP (red dots) (ratio 1:50,000) were visualized in the cytoplasm
(green color) but not in the nuclei (blue color) of the A549 cells after 48h of incubation. A rep-
resentative orthogonal analysis is shown in Fig 3D to emphasize the internalization of MP.
Following the same experimental design as described above, lung fibroblasts from IPF
patients also showed a high uptake efficacy of MP in non-stimulated condition (Fig 4A) with
non-significant difference between 24 or 48 h of incubation time at doses of 1:50,000 and
Fig 1. Characterization of physical and molecular properties of MP from AT-MSC. (A) Cryo-electron microscopy images of MP. MP show a spherical shape and a
discernible lipid bilayer. (B) A representative profile of the nanoparticle tracking analysis (NTA) of MP. MP are visualized by light scattering using a light microscope. A
video is taken, and the NTA software tracks the brownian motion of individual MP and calculates their size and total concentration (particles/ml). A graph was
generated by plotting the distribution in size of the MP against the concentration. (C) STRING analysis (http://www.string-db.org) derived protein-protein interaction
networks for 5 proteins that are involved in regulation of the extracellular matrix organization. The network nodes represent proteins. Edges represent protein-protein
associations. The associations are meant to be specific and meaningful with associated proteins jointly contributing to a shared function. This does not necessarily mean
that the proteins are physically binding each other. (D) MMP activity was measured in MP using a fluorimetric assay. MMP activity was activated with APMA and
inhibited with GM6001. Results are expressed as mean ± SD.
https://doi.org/10.1371/journal.pone.0248415.g001
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1:100,000 MP per cell. Furthermore, TGF-β stimulation did not modify the uptake efficacy of
MP by the cells (Fig 4B). Fig 4C shows the confocal images analysis at 48 h of incubation with
TGF-β and MP at 1:50,000 dose and Fig 4D the internalization the MP by orthogonal analysis.
Taking together, the data from the toxicity assay, flow cytometry and confocal images, a
dose of 50,000 MP per single cell was finally chosen for the following experiments.
MP treatment reduces TGF-β-induced pro-fibrotic markers in A549 cells
A549 cell line was incubated for 48 h with MP from AT-MSC (1:50,000 cell:MP) and stimu-
lated simultaneously with TGF-β (5 ng/ml). The modulation of genes involved in pro-(Fig 5A)
and anti-fibrotic (Fig 5B) processes by MP was analyzed. As shown in Fig 5A TGF-β increased
gene expression of the pro-fibrotic markers Collagen type I (Col 1A1), Collagen type III (Col
3A1), Fibronectin, and Plasminogen activator inhibitor 1 (PAI-1) with respect to the non-
stimulated A549 culture (Control). MP treatment in TGF-β stimulated cells resulted in a sig-
nificant gene expression decrease of these markers with respect to TGF-β control. Moreover,
MP alone did not induce any pro-fibrotic response in non-stimulated cells resulting in a simi-
lar gene expression profile as control cells.
In Fig 5B, the anti-fibrotic markers (TERT, E-cadherin and MMP-7) were downregulated
by TGF-β. When the gene expression of E-cadherin was studied, we did not find a recovery by
MP of the inhibition provoked by TGF-β; which suggests that the epithelial mesenchymal tran-
sition (EMT) pathway activated by TGF-β was not reversible by the action of the MP. How-
ever, TGF-β no-stimulated cells treated with MP were able to express significant higher levels
of E-cadherin compared to control. MMP-7 expression levels in TGF-β non-stimulated cells
were decreased as compared to control, no significant results were found when cells were
treated with MP in combination with TGF-β. Finally, when A549 cells were treated with MP, a
significant increase in the gene expression of the telomerase component as compared to
untreated cells was observed. However, MP were not able to recover the decrease of TERT
gene expression induced by TGF-β at the control level.
MP treatment decreased TGF-β fibrotic markers in human lung fibroblast
Following the same protocol as explained for epithelial cells, primary lung fibroblasts from
patients with normal (FN) and short (FS) telomere length were analyzed under TGF-β with
Fig 2. Effect of MP in the viability of human lung cells. Bronchial epithelial cells (A549) (A) and lung fibroblasts from normal (FN) telomere length patients (B) and
short telomere length (FS) patients (C) were stimulated with different doses of MP for 48h. No significant toxicity was observed for any of the doses assayed; 1:10,000
ratio cells:MP (lighter grey bars), 1:50,000 ratio cell:MP (grey bars) and 1:100,000 ratio cell:MP (black bar) compared to PBS treatment (white bars). Bars represent the
mean values ± SEM of optical density at 420 nm in three independent experiments.
https://doi.org/10.1371/journal.pone.0248415.g002
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MP stimulation. TGF-β induced up-regulation of all the pro-fibrotic markers in lung fibro-
blasts analyzed by gene and protein expression compared to the TGF-β non-stimulated control
(Fig 6). Interestingly, fibroblast from FN and FS IPF patients had different responses in the
modulation of the pro-fibrotic gene expression markers after TGF-β stimulation. Comparing
the gene expression profile between FN and FS, three different responses were obtained. Fig
6A shows a similar pattern of the gene expression by the two types of fibroblasts. TGF-β stimu-
lation provoked an increase of the pro-fibrotic markers COL 1A1, Tenascin-c, and PAI-1, that
was reduced when cells were treated with MP. Moreover, there was a decrease in the anti-
fibrotic protein, MMP-1, in cells stimulated with TGF-β that was reverted in MP treatment
conditions. For the pro-fibrotic markers α-SMA, PD-L1, and Fibronectin, FN fibroblasts
showed a higher modulatory response after MP treatment when compared to FS cultures. For
these proteins, it seems that FS fibroblasts were not able to inhibit the TGF-β increase when
cells were treated with MP (Fig 6B). Finally, there were two pro-fibrotic markers COL 3A1 and
TGF-β, which showed a statistically significant decrease of gene activation by TGF-β after MP
treatment in FS but not in FN fibroblasts (Fig 6C).
Fig 3. Uptake analysis of MP by A549 cells. AT-MSC were labeled with PKH-26 before generation of MP (PKH-MP). PKH-MP were added to A549 cells (cell:MP
ratios 1:10,000; 1:50,000 and 1:100,000) and incubated for (A) 24 and 48 h. Uptake of PKH-MP by A549 cells was quantified using flow cytometry. Uptake is indicated
by PKH-MP positive cells. (B) 48 h under TGF-β stimulation. (C) Representative confocal microscopy analysis of PKH-MP uptake by A549 cells at time point 48 h and
with or without TGF-β stimulation. Staining for PKH-MP (red), cytoplasm (green), and Hoechst 33342 nuclei (blue) showed that PKH-MP are internalized by A549
cells.(D) Orthogonal view from different planes of the confocal microscope images to analyze the particle uptake. Co-localization of green fluorescent CFSE and red
PKH-MP is observed in the cytoplasm. Levels of significance: � p< 0.05 respect to the ratio 1:50,000, and 1:100,000 cell:MP.
https://doi.org/10.1371/journal.pone.0248415.g003
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The gene expression of vimentin was also analyzed, but MP did not induce any significant
difference when compared to TGF-β stimulated cells (data not shown).
Some of the markers analyzed by qPCR were then studied for protein expression. The pro-
tein concentration of Tenascin-c (Fig 7A) and MMP-1 (Fig 7B) was analyzed in the superna-
tant of the fibroblast cultures, and levels of Fibronectin protein were analyzed in cell lysates
(Fig 7C and 7D). The levels of Tenascin-c and Fibronectin were reduced by MP treatment
under TGF-β stimulation in FN and FS, and the concentration of anti-fibrotic MMP-1 protein
was increased in both types of fibroblasts. These results supported the gene expression data.
Discussion
Despite constant efforts, many therapeutic approaches for IPF patients failed until anti-fibrotic
therapy altered the management of this devastating disease. Currently, pirfenidone and ninte-
danib are the only approved drugs that slow down IPF progression [11–13], but there is no
definitive cure for avoiding the lethality of the disease. Furthermore, the patient response to
anti-fibrotic treatment is heterogeneous [9], stressing the need to establish novel therapeutic
Fig 4. Uptake of PKH-MP by human lung fibroblasts. PKH-MP uptake by fibroblast was analyzed by flow cytometry at the time points (A) 24 and 48 h. (B) 48 h under
TGF-β stimulation. (C) In vitro internalization of PKH-MP into human fibroblasts at 48 h time point and with or without TGF-β stimulation. PKH-MP are shown as
red color, cell membrane (green), and Hoechst 33342 nuclei (blue). (D) Representative orthogonal analysis. Levels of significance: � p< 0.05 respect to the ratio
1:50,000, and 1:100,000 cell:MP.
https://doi.org/10.1371/journal.pone.0248415.g004
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approaches. The present in vitro study demonstrates that MP from AT-MSC can ameliorate
TGF-β induced fibrotic responses in human lung epithelial cells and fibroblasts by reducing
the gene expression of proteins involved in fibrogenesis.
A growing body of experimental and preclinical studies on lung pathologies, including IPF,
supports the efficacy of the administration of MSC from different sources such as bone mar-
row [14], placenta [19], lung tissue [15], and adipose tissue [18]. These studies show that MSC
administration, independently of the cell source, is safe and have a beneficial effect in fibrotic
lung diseases. The authors reported that MSC should be infused early in the disease course
[36], during active inflammation and before significant fibrotic changes [37]; otherwise, MSC
might acquire a myofibroblast phenotype and contributed to fibrotic changes during the
fibrotic phase of the disease [37].
Several studies described the comparison of MSC properties derived from different tissue
origin [38–40]. However, there is still a concern about which tissue provides the most appro-
priate type of MSC for therapy. We have observed that AT-MSC had the best proliferation rate
in culture, and same immunomodulatory properties when comparing to other MSC sources
such as umbilical cord and bone marrow [41]. Mediating the regenerative properties of
AT-MSC through MP could offer several physiological advantages such as reducing the risk of
cellular dysfunction because MP lack the capacity to proliferate. Furthermore, MP are unable
to modify their behavior in response to the environment, making MP therapy better controlla-
ble than MSC therapy. The methodology described herein allowed obtaining MP with intact
transmembrane protein as observed by the detection of the metalloproteinase enzyme activity,
thereby exploiting some of the natural regenerative properties of AT-MSC.
Another beneficial characteristic of MP is that they were effectively taken up in large quan-
tities by alveolar epithelial cells (A549) and lung fibroblasts from IPF patients without inducing
cytotoxic effects. As shown in the confocal microscopy images, there was the internalization of
Fig 5. MP effect in gene expression in bronchial epithelial cells. A549 cells were cultured with 1:50,000 cell:MP ratio
and TGF-β (5 ng/ml) for 48 h. Gene expression of different markers involved in ECM remodeling pathways was
analyzed by qPCR. (A) The pro-fibrotic markers Col1A1, Col3A1, fibronectin and PAI-1. (B) The anti-fibrotic
molecules TERT, E-cadherin, and MMP7. Bars represent mean values ± SEM fold changes expressed as relative gene
expression (RGE) of three different experiments. Levels of significance: � p< 0.05, �� p< 0.01; ��� p< 0.001. �
indicates the comparison between control and MP treated cells or TGF-β stimulated cells compared to the
combination of TGF-β and MP.
https://doi.org/10.1371/journal.pone.0248415.g005
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Fig 6. MP effect on gene expression in human lung fibroblasts. Lung fibroblasts from patients with normal (FN) and short (FS) telomere length were stimulated with
1:50,000 cell:MP ratio and with or without TGF-β (5 ng/ml) for 48 h. Gene expression was assayed by qPCR. (A) Comparison of two types of fibroblasts showing a
similar profile in the modulation of pro-fibrotic markers; COL 1A1, tenascin-c, and PAI-1 and the anti-fibrotic MMP-1 gene. (B) Higher response in gene expression of
α-SMA, PDL-1 and fibronectin markers in FN than FS cultured cells. (C) Differential modulation in gene expression of COL 3A1 and TGF-β showing FN culture lower
response compared to FS. Grey dashed line represents the normalization based on the gene expression level of untreated control according to the ΔΔCt method. Chars
represent mean values ± SEM fold changes expressed as relative gene expression (RGE) of nine different experiments. Levels of significance: � p< 0.05, �� p< 0.01; ���
p< 0.001. � indicates the comparison between TGF-β stimulated cells compared to TGF-β and MP.
https://doi.org/10.1371/journal.pone.0248415.g006
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MP into lung cells. Previously, we have observed that macrophages and endothelial cells
appear to take up MP by a variety of endocytic pathways, including clathrin-dependent endo-
cytosis, and clathrin-independent pathways such as caveolin-mediated uptake, and phagocyto-
sis [42]. These mechanisms of internalization, shared with EV [43], support the idea that MP
may be used as well as delivery vehicle for lung cells-targeting drugs with inherent anti-fibrotic
effects.
We used the A549 cell line to study the effect of MP on cell-released proteins. Although the
A549 cell line is from a cancer patient, it has been broadly used to model alveolar type II epi-
thelial cells behavior [44, 45]. MP decreased the gene expression of profibrotic proteins such as
Col 1A1, Fibronectin and PAI-1 in A549 cells. However, MP did not achieve a recovery of E-
cadherin expression after its inhibition by TGF-β, indicating that the EMT pathway is not
totally abolished with MP treatment. Several groups described similar findings on A549 cells
using pirfenidone, suggesting that the E-cadherin inhibition by TGF-β might not be reversible
[46, 47]. An important result in our study was the increase in TERT expression in A549 cells
after MP treatment in non TGF-β stimulated condition.
Fig 7. MP effect in protein levels. Fibroblasts from IPF patients with normal (FN) and short (FS) telomere length were stimulated with TGF-β (5 ng/ml) and 1:50,000
cell:MP ratio for 48 h. Protein levels in supernatants were analyzed by ELISA for tenascin-c (A), and MMP-1 (B). Protein expression of fibronectin in cell extracts was
analyzed by Western blot, bars of fibronectin values normalized with vinculin expression (C), representative Western blot images of one TGF-β stimulated sample and
two different TGF-β-MP treated samples (D). Chars represent mean values ± SEM of nine independent experiments. Levels of significance: � p< 0.05, �� p< 0.01 ���
p< 0.001. � indicates the comparison between TGF-β stimulated cells compared to TGF-β and MP.
https://doi.org/10.1371/journal.pone.0248415.g007
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It has been described that the dysfunction of telomerase associates telomere attrition and,
as a result, accelerate aging in these cells [48–50]. By enhancing TERT expression in epithelial
cells, MP might have a protective role against senescence and potentially favor the recovery of
the alveolus architecture.
Fibroblasts from IPF patients with different telomere length were used to analyze the anti-
fibrotic role of MP in TGF-β stimulated cultures. It has been described that telomere length is
correlated with the clinical outcome of IPF patients [5]. We found different effects of MP in
fibroblasts of patients with long and short telomeres. Thus, some of the markers decreased in
FN upon MP treatment; such as α-SMA, PD-L1 and Fibronectin, but others were significantly
reduced in FS; Col 3A1 and TGF-β. However, for most of the important pro-fibrotic markers
both types of fibroblasts had the same inhibitory response after MP treatment Col 1A1, Tenas-
cin-c, PAI-1 and an activation of anti-fibrotic MMP-1 gene expression. It has been described
that aging is a key factor in IPF, and lung fibroblasts from old mice exhibit a fibrogenic pheno-
type that leads to increased susceptibility to fibrosis after injury [16, 51, 52]. The differential
response shown by the fibroblasts in this study might be due to different cell behavior depend-
ing on biological age, including the patient telomere attrition. Little is known about the differ-
ent IPF fibroblast function depending on aging hallmarks, and the present study stratified the
lung fibroblastic response depending on the patient telomere length. Thus, one might hypoth-
esize that FS have a more severe fibrotic response after TGF-β. MP treatment was able to
inhibit the TGF-β increased gene expression by decreasing the levels of the pro-fibrotic factors
involved in fibrogenesis. MP may be a suitable option for attenuating the fibrotic response in
IPF patients with normal and short telomere length. Further studies are needed to better char-
acterize the molecular implication of MP in the inhibition of TGF-β mediated fibrosis.
These results are in agreement with a previous study of our group that showed a decrease in
pro-fibrotic markers in lung cells that were stimulated with a combination of pirfenidone and
rapamycin in a similar TGF-β induced in vitro model of fibrosis [53]. This suggests that MP
treatment have a comparable modulatory effect of the main ECM proteins involved in the
fibrotic pathway to these conventional drugs.
Although our results seem promising, this in vitro study is a proof-of-concept about the
potential effect of MP in the lung cell pro-fibrotic response and present several limitations.
First, in vitro studies are needed to improve our understanding about the mechanisms of
action of the MP. However, we might assume that the transmembrane proteins present in the
MP have a role in the modulation of many cell pathways by comparing with the findings
reported in several EV studies [54–56]. Second, in vivo studies should be performed to further
support the role of MP as a potential anti-fibrotic therapy.
In conclusion, MP represent a nano-size version of MSC membranes that conserve some of
the therapeutic properties attributed to the living MSC. Our data demonstrates that MP target
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